Table 1.
Baseline characteristics of 1055 patients with newly diagnosed second stage human African trypanosomiasis treated with eflornithine in Ibba, southern Sudan. Values are numbers (percentages) of patients unless stated otherwise
| Characteristics | Patients with sleeping sickness (n=1055) |
|---|---|
| Women | 468 (44) |
| Median (interquartile range) age (years) | 22 (15-32) |
| Age <15 years | 226 (21) |
| Median (interquartile range) weight (kg) | 46 (38-54) |
| County of residence: | |
| Mundri | 676 (64) |
| Maridi | 276 (26) |
| Other | 103 (10) |
| Detected by active screening | 121 (12) |
| Malaria coinfection | 445 (42) |
| Axillary temperature ≥37.5°C | 357 (34) |
| Glasgow coma score* (n=1012): | |
| 10 | 7 (1) |
| 11 | 1 (0.1) |
| 12 | 2 (0.2) |
| 13 | 6 (1) |
| 14 | 22 (2) |
| 15 | 974 (96) |
| Localisation of trypanosomes: | |
| Lymph nodes | 683 (65) |
| Blood | 330 (31) |
| Lymph or blood | 1005 (95) |
| Cerebrospinal fluid | 351 (33) |
| Leucocyte count in cerebrospinal fluid: | |
| Geometric mean×109/l | 43.9 |
| ≤20×109/l | 450 (43) |
| 21-99×109/l | 256 (24) |
| ≥100×109/l | 349 (33) |
*Score is sum of points obtained in each of three criteria (best motor response, best verbal response, eye opening): 3-8=severe impairment; 9-12=moderate impairment; 13-14=mild impairment; and 15=normal.